Majcher A, Deptała A, Konopka L, Pawelski S
Klinika Chorób Wewnetrznych Instytutu Hematologii, Warszawa.
Acta Haematol Pol. 1991;22(1):82-91.
In 6 women aged 38 to 68 years with thrombocythaemia during chronic myeloid leukaemia (4 cases), myelofibrosis (1 case), and idiopathic thrombocythaemia (1 case) the effects of recombinant human alpha-interferon (Intron A, rh IFN alpha -2b, Schering) were studied. The drug was given to all patients subcutaneously in one daily dose of 3 x 10(6) u, every day for 3 weeks, and then in the same doses twice weekly for 2 weeks (5 cases) and for 14 weeks (1 case). Intron A caused in all cases a fall of peripheral blood platelet count by 37% to 65.5% (mean 50%) in relation to the initial count (532 - 1,453 x 10(9)/l). The fall of the platelet count occurred usually after 7-10 days of this treatment, and the lowest count was noted usually after 24 days (10 to 42 days). During the treatment in 4 cases the peripheral leucocyte count dropped as well by 20-70%. In no cases exacerbation of chronic myeloid leukaemia was noted, and in the patient with myelofibrosis the enlarged spleen shrunk somewhat. These results of treatment and follow-up of patients with thrombocythaemia treated with Intron A indicate a significant although short-lasting effect of platelet count fall limited, however, to the time of the treatment. Side effects of the drug included mainly febrile conditions, myalgia and arthralgia.
对6名年龄在38至68岁之间、患有慢性粒细胞白血病（4例）、骨髓纤维化（1例）和原发性血小板增多症（1例）并发血小板增多症的女性患者，研究了重组人α干扰素（英特龙A，rh IFNα -2b，先灵公司）的疗效。所有患者均皮下注射该药，每日剂量为3×10⁶单位，连续3周每天用药，然后以相同剂量每周两次用药2周（5例）和14周（1例）。英特龙A在所有病例中均使外周血血小板计数相对于初始计数（532 - 1453×10⁹/L）下降了37%至65.5%（平均50%）。血小板计数通常在该治疗7 - 10天后开始下降，最低计数通常在24天（10至42天）时出现。治疗期间，4例患者的外周白细胞计数也下降了20 - 70%。未观察到慢性粒细胞白血病病情加重的情况，骨髓纤维化患者肿大的脾脏有所缩小。这些使用英特龙A治疗血小板增多症患者的治疗及随访结果表明，血小板计数下降有显著但持续时间较短的效果，不过仅限于治疗期间。该药的副作用主要包括发热、肌痛和关节痛。
